

Oxurion NV: Key developments and timeline for current the potential acquisition

LEUVEN, BELGIUM - October 29, 2024 - 10:00 pm, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces that it has completed the due diligence phase concerning the acquisition of an 80% majority stake in a CRO (Contract Research Organisation), following the signature of a letter of intent (see press release of July 8, 2024).

The results of this due diligence phase have been conclusive, enabling Oxurion to progress towards a potential signing of the transaction by November 30, 2024.

In addition, an application for Foreign Direct Investment (FDI) authorization was filed with the French authorities on October 2, 2024, in accordance with the requirements of article L. 151-3 of the French Monetary and Financial Code, - given that the target company could be considered of strategic national interest. This request is currently under review.

The next key steps are as follows:

- Finalization of negotiations on the Sales & Purchase Agreement (SPA) and the shareholders' agreement within the acquisition holding company, in which Oxurion will hold 80% of the capital alongside the historical shareholders.
- Finalization of the financing of the transaction.

Oxurion will continue to inform the market and its shareholders of any important developments concerning this planned transaction.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV
Pascal Ghoson
Chief Executive Officer
Pascal.ghoson@oxurion.com